→ Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze “late last year,” the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Preliminary data showed that viltolarsen (Viltepso), an exon-skipping drug that won accelerated approval to treat Duchenne muscular dystrophy in 2020, failed a 48-week phase III
20mg/ml injections of Bizengri will be available to patients in coming weeks. Credit: aslysun / Shutterstock. Merus’ Bizengri (zenocutuzumab-zbco) has received accelerated approval from the
Hamilton, a leading global manufacturer of precision measurement devices, automated liquid handling workstations, and sample management systems, is excited to announce the release of its